The Colon Club

A new MSS-CRC immunotherapy trial - NCT02903914.

A novel mechanism, an "arginase inhibitor" named "CB-1158". Arginase is immunosupressive and it has been known for years to be a clinical marker for CRC - so they are specifically recruiting MSS-CRC patients for an arm of the trial. I am glad for the steady increasing focus on MSS-CRC in immunotherapy clinical trials! My guess is that they will eventually test it in combination with PD1 in MSS-CRC patients but they are only testing CB-1158 alone to start (in CRC)...

https://clinicaltrials.gov/ct2/show/NCT ... 914&rank=1

-DK

I love that there are more irons in the fire for MSS. Thanks for sharing DK. It's news I love to read!

Thank you for the information DK37. This does sound encouraging. CB-1158 may become one part of a combination immunotherapy strategy for MSS-CRC.